Fig. 6

ICI blunts tumor growth more effectively than T6I-29–1 A. Female NOD/SCID mice received silastic E2 pellet surgery one week prior to cell injection. ESR1 MCF7 Y537S cells with a luciferase tag were injected bilaterally into mammary fat pad #4. A) Tumor growth (error bars represent SEM) in vehicle, T6I-29–1 A, and ICI treatment groups (n = 17–20 tumors/ group). Significance is measured by Two-Way Anova with Bonferroni post-hoc test. B) Final uterine weights (n = 10 mice/ group). Significance is measured by Anova with Tukey post-hoc test. C) Survival curve compared to vehicle. Log Rank test used to determine significant survival benefit. Veh vs. T6I-29–1 A: p = 0.0966, Veh vs. ICI: p = 0.0001, T6I-29–1 A vs. ICI p = 0.0052. D) Representative weekly IVIS bioluminescent imaging denoting weekly tumor growth. Scale bar shown on right. E) Quantified luminescence for each treatment group (error bars represent SEM). Significance was determined using unpaired t test at each week with Mann-Whitney correction. F) Ex vivo metastatic luminescence at common sites (liver, femurs, uterus, brain) for each mouse. Anova with Tukey post-hoc was used to determine significance